Biogen Submits Biologics License Application to U.S. FDA for aducanumab as treatment of Alzheimer’s disease

Submission for this human IgG1 monoclonal antibody selective for fibrillar form of beta amyloid includes data from phase III EMERGE and ENGAGE trials, as well as phase Ib PRIME study. Discussions are also underway with European Medicines Agency.


Biospace Inc.